[The role of copper in the pathophysiology of Alzheimer's disease]. / Zur Bedeutung von Kupfer für die Pathophysiologie der Alzheimer-Krankheit.
Nervenarzt
; 76(5): 581-5, 2005 May.
Article
en De
| MEDLINE
| ID: mdl-15905983
Alzheimer's dementia (AD) is a chronically progressive neurodegenerative disease. The key protein in the pathophysiology of AD is the amyloid precursor protein (APP) which releases the amyloid-beta peptide (Abeta) by proteolytic cleavage. APP is probably involved in the homeostasis of cellular copper (Cu) metabolism, because significantly changed Cu levels in the brain were found in AD patients as well as in mouse models. In vivo studies with transgenic mice showed that oral Cu supplements can restore lowered Cu levels in the brain to normal, can reduce Abeta production, and can reduce mortality of the animals. Currently, the influence of oral Cu supplementation (in addition to an established acetylcholinesterase inhibitor) on the progression of the disease is being studied in a prospective, double-blind, randomized and placebo-controlled longitudinal clinical trial in patients with mild AD.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Encéfalo
/
Péptidos beta-Amiloides
/
Cobre
/
Enfermedad de Alzheimer
Tipo de estudio:
Clinical_trials
Límite:
Animals
/
Humans
Idioma:
De
Revista:
Nervenarzt
Año:
2005
Tipo del documento:
Article
Pais de publicación:
Alemania